Do Not Initiate C5 Inhibition at This Time—Wait for mHAM 2.0 Results and Establish a Definitive Diagnosis
The decision to initiate complement C5 inhibition (eculizumab or ravulizumab) should be deferred until the mHAM 2.0 results confirm the diagnosis of atypical hemolytic uremic syndrome (aHUS), as the current clinical presentation does not meet established criteria for emergent treatment initiation.
Rationale for Deferring Treatment
Diagnostic Uncertainty is Critical
The patient's presentation is ambiguous. While low-grade hemoglobinuria and two stage 1 AKI episodes raise concern, stage 1 AKI alone does not constitute an indication for C5 inhibition without confirmed complement-mediated thrombotic microangiopathy (TMA). The Italian multidisciplinary consensus 1 emphasizes that C5 inhibitors should be initiated when aHUS is diagnosed based on clinical suspicion of TMA with supporting laboratory evidence—specifically thrombocytopenia, evidence of hemolysis (elevated LDH), and acute kidney injury.
Your patient currently has:
- No anemia (despite hemoglobinuria)
- No documented thrombocytopenia
- Only stage 1 AKI (the mildest form, with creatinine 1.5-1.9× baseline)
- Unexplained ketonuria (which is not a feature of aHUS)
The mHAM 2.0 is Pending—This is Decisive
The modified hemolysis assay (mHAM) 2.0 is specifically designed to detect complement dysregulation and can identify patients who will benefit from complement inhibition. Initiating expensive, lifelong therapy with significant infection risk (particularly meningococcal disease) before confirming the diagnosis is not justified 1.
Stage 1 AKI Does Not Require Emergent Intervention
According to ADQI guidelines 2, patients with stage 1 AKI should be managed conservatively with:
- Withdrawal of nephrotoxic medications (if any)
- Optimization of volume status
- Treatment of any underlying infections
- Close monitoring of renal function
The patient has known risk factors for recurrent AKI (previous AKI episodes, hypertension) 2, which makes her vulnerable, but this alone does not indicate complement-mediated disease requiring C5 blockade.
What to Do Now: A Specific Management Algorithm
1. Complete Diagnostic Workup Before Treatment
- Wait for mHAM 2.0 results to confirm complement dysregulation
- Obtain genetic testing for complement pathway mutations (CFH, CFI, MCP/CD46, C3, CFB) 1, 3
- Measure complement levels: C3, C4, CH50, AP50 (alternative pathway activity)
- Check for anti-factor H antibodies (6-10% of aHUS cases in pediatrics are antibody-mediated) 4
- Rule out other causes of hemoglobinuria: paroxysmal nocturnal hemoglobinuria (PNH) with flow cytometry, intravascular hemolysis workup
- Investigate the unexplained ketonuria: This is atypical for aHUS and suggests an alternative metabolic process that needs evaluation
2. Supportive Management for Stage 1 AKI
Following ADQI consensus recommendations 2:
- Review all medications: Discontinue or reduce any nephrotoxins, NSAIDs, or drugs that could exacerbate AKI
- Optimize blood pressure control: The patient has secondary hypertension—ensure adequate control without causing hypotension that could worsen renal perfusion
- Monitor renal function closely: Check creatinine every 2-4 days initially, then weekly
- Avoid volume depletion: Ensure adequate hydration without causing volume overload
3. Establish Criteria for Treatment Initiation
Only initiate C5 inhibition if:
- mHAM 2.0 confirms complement dysregulation, AND
- Clinical evidence of TMA develops:
- Thrombocytopenia (platelets ≤150 × 10⁹/L) 5
- Evidence of hemolysis (elevated LDH, schistocytes on blood smear, decreased haptoglobin)
- Worsening AKI (progression to stage 2 or 3)
- Development of anemia
4. If aHUS is Confirmed: Pre-Treatment Requirements
Before initiating C5 inhibition 1, 5:
- Meningococcal vaccination: Quadrivalent A, C, W, Y vaccine (required due to increased infection risk with terminal complement blockade)
- Consider prophylactic antibiotics until vaccination is effective (typically 2 weeks)
- Screen for C5 polymorphisms if patient is of Chinese or Japanese descent (c.2654 G→A, c.2653 C→T variants cause resistance to anti-C5 antibodies) 1
Why the Nephrologists Are Correct to Hesitate
The two nephrologists' reluctance is clinically sound. C5 inhibitors are not benign therapies:
- Lifelong treatment may be required (though discontinuation can be considered in select cases after 3+ months of stability) 1
- High cost: Ravulizumab and eculizumab are among the most expensive medications available
- Serious infection risk: Particularly invasive meningococcal disease, which can be fatal
- Uncertain benefit without confirmed diagnosis: Treating empirically without diagnostic confirmation exposes the patient to risks without proven benefit
The hematologist's recommendation to treat may reflect concern about potential progression, but in the absence of active TMA, watchful waiting with close monitoring is the appropriate standard of care 1, 6.
Special Considerations
The Unexplained Ketonuria
This finding is not consistent with aHUS and warrants separate investigation:
- Rule out occult diabetes (check HbA1c, fasting glucose, consider oral glucose tolerance test)
- Consider inborn errors of metabolism (though less likely in an otherwise healthy adult)
- Evaluate for eating disorders or intermittent fasting patterns
- Check thyroid function (hyperthyroidism can cause ketonuria)
The Low-Grade Hemoglobinuria Without Anemia
This pattern is unusual for active aHUS, which typically presents with both hemolysis and anemia. Consider:
- PNH (paroxysmal nocturnal hemoglobinuria)—flow cytometry is essential
- Chronic intravascular hemolysis from other causes (mechanical heart valves, march hemoglobinuria, etc.)
- Myoglobinuria misidentified as hemoglobinuria
Secondary Hypertension
This requires investigation for underlying causes:
- Renal artery stenosis
- Primary aldosteronism
- Pheochromocytoma
- Chronic kidney disease from prior AKI episodes
Monitoring Plan While Awaiting Diagnosis
Weekly for the first month:
- Serum creatinine, BUN
- Complete blood count with platelet count
- LDH, haptoglobin
- Blood pressure monitoring
Every 2 weeks thereafter:
- Same laboratory parameters
- Urinalysis for hemoglobinuria and proteinuria
Immediate evaluation if:
- Thrombocytopenia develops
- Anemia develops or worsens
- AKI progresses to stage 2 or higher
- New neurological symptoms appear
If Treatment Becomes Necessary: Ravulizumab vs. Eculizumab
Should aHUS be confirmed and treatment required, ravulizumab is preferred over eculizumab 5, 6, 3:
- Longer dosing interval: Every 8 weeks vs. every 2 weeks for eculizumab
- Immediate and sustained C5 inhibition from the first dose
- Comparable efficacy and safety to eculizumab
- Lower treatment burden for patients and caregivers
- Potentially lower long-term costs due to less frequent administration
The FDA label data 5 demonstrates that ravulizumab achieves complete terminal complement inhibition and maintains it throughout the dosing interval in both treatment-naïve and eculizumab-experienced patients with aHUS.
Common Pitfalls to Avoid
- Do not treat empirically without diagnostic confirmation—the risks outweigh benefits in the absence of active TMA
- Do not dismiss the nephrologists' concerns—their caution reflects appropriate clinical judgment
- Do not delay vaccination if treatment becomes necessary—meningococcal infection can be fatal in complement-inhibited patients
- Do not ignore the atypical features (ketonuria, absence of anemia)—these suggest alternative or additional diagnoses
- Do not assume stage 1 AKI requires aggressive intervention—conservative management is appropriate 2